Page 179 - CW E-Magazine (21-11-2023)

Document

quality at low cost” to “exceptional ative, the policy aims to fortify a paradigm shift in the Indian pharma
quality at highest value”. This would national capabilities and sovereignty, industry, moving from the conventional
come from focus on innovation and, endorsing the ‘Make in India’ drive approach of “incremental innovation”
at the same time, retain the cost com- to ensure self-sufficiency in pharma to embracing “disruptive innovation”
petitiveness and scale of India’s generic production with renewed focus on with the introduction of novel drugs,
advantage. quality. devices, and technologies and esta-
3. Advancing health equity and acces- blishing “Innovation-Hubs” in India.
Achieving Vision@2047 as set forth sibility: The policy is committed
by Honourable Prime Minister will to advancing health equity by en- The policy envisages to promote
require diligent and focused implemen- suring that quality medicines and R&D in India and complement the
tation beginning from the development healthcare services are accessible Department’s National Policy on R&D
of detailed work plans, charters, and a and affordable to all citizens, reduc- and Promotion of Research and Inno-
governance framework that continu- ing disparities in healthcare access. vation in the Pharma-MedTech Sec-
ously engages all stakeholders in the 4. Attracting Foreign Direct Invest- tor (PRIP) Scheme. It aims to create a
government, industry, and academia. ments: One of the key objectives is supportive ecosystem purpose-built to
Realising this vision will need the sup- to create an environment conducive bolster innovation and cross-sectoral
port of the right set of enablers which to attracting foreign investments in research serves as a solid institutional
NPP 2023 aims to address. A coherent the Indian pharma sector, fostering foundation for ensuring sustainable
policy framework is vital to ensure that economic growth, innovation, and growth within the sector by:
Indian pharma companies can adapt to global collaborations. Building innovation infrastructure
these changes swiftly, maintain inter- 5. Enhancing regulatory efficiency: such as Bulk Drugs Parks, Develop-
national compliance, and consistently The policy underscores the har- ing Centre’s of Excellence (CoEs)
deliver high-quality, safe, and effica- monisation of regulatory approvals in academic and research institu-
cious medicines. and an emphasis on transparency in tions, innovation hubs for research,
pricing mechanisms, streamlining technology validation, and product
The policy not only promotes regu- processes, and promoting ease of development.
latory efficiency, research, and innova- doing business in the pharma indus- Foster collaboration between aca-
tion, but also ensures equitable access try’s regulatory framework. demia and industry to drive innova-
to medicines, strengthens healthcare tion and research.
self-sufficiency, and enhances India’s FOCUS AREAS Promoting and facilitating multi-
global standing in the pharma sector. lateral cooperation in affordable,
It is a critical tool to propel the nation Nurturing & Promoting Research, sustainable manner and quality
towards a healthier, more prosperous Development & Innovation R&D for coordinated approaches
future, where healthcare is both acces- The policy is dedicated to creating in fighting emerging disease threats
sible and of the highest quality. an environment where pharma research and capacity building in medical
flourishes, innovation is incentivised, countermeasures.
OBJECTIVES and new frontiers in healthcare are Contribute to health system to attain

The objectives of the NPP 2023 are continually explored. Through strate- union of equity, efficacy, and effi-
as under: gic investments, collaborative partner- ciency towards developing holistic
1. Fostering global pharma leader- ships, and incentives for R&D, it seeks product profile, with focus on non-
ship: The policy envisions India’s to elevate India’s pharma industry to an communicable diseases (NCDs),
transformation into a prominent era of innovation-led growth. By sup- AMR, and rare & neglected
global R&D hub for the pharma porting and fostering talent within the diseases along with renewed focus
industry, shifting from a volume- country, while also encouraging inter- on achieving leadership in m-RNA
based to a value-based leadership national collaborations, this policy not technologies, cell-gene therapy,
model, underpinned by world class only advances India’s self-reliance, but other emerging technologies etc.
research infrastructure, thereby en- also positions the nation as a pioneering Encouraging public-private partner-

hancing the nation’s global stand- force in driving transformative health- ships, increasing funding for re-
ing. care solutions, ultimately benefiting search, and providing tax incentives
2. Promoting self-reliance: Aligned both its citizens and the global com- to boost domestic drug discovery
with the Atmanirbhar Bharat initi- munity. The policy aims to encourage and innovation.

Chemical Weekly November 21, 2023 179

Contents Index to Advertisers Index to Products Advertised